Sugi Predict

Sugi Predict / Targets / MAN1B1

MAN1B1

Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase · Q9UKM7 · MAN1B1 on Sugi Atlas →

1,496 patent compounds predicted against MAN1B1, 725 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13808578 SCHEMBL13808578 1.00 17/20
SCHEMBL13808575 SCHEMBL13808575 0.85 17/20
SCHEMBL3994042 SCHEMBL3994042 0.76 17/20
SCHEMBL3997325 SCHEMBL3997325 0.64 16/20
SCHEMBL4286219 SCHEMBL4286219 0.71 15/20
SCHEMBL13808576 SCHEMBL13808576 0.51 15/20
SCHEMBL4001127 SCHEMBL4001127 0.71 14/20
SCHEMBL4001130 SCHEMBL4001130 0.71 14/20
SCHEMBL2433156 SCHEMBL2433156 0.57 12/20
SCHEMBL8599119 SCHEMBL8599119 0.51 10/20
SCHEMBL11190081 SCHEMBL11190081 0.47 9/20
SCHEMBL4129418 SCHEMBL4129418 0.59 7/20
SCHEMBL15574485 SCHEMBL15574485 0.40 7/20
SCHEMBL15517611 SCHEMBL15517611 0.38 6/20
SCHEMBL20470481 SCHEMBL20470481 0.64 5/20
SCHEMBL21578193 SCHEMBL21578193 0.64 5/20
SCHEMBL21578194 SCHEMBL21578194 0.64 5/20
SCHEMBL15593211 SCHEMBL15593211 0.50 5/20
SCHEMBL15593229 SCHEMBL15593229 0.50 5/20
SCHEMBL19557582 SCHEMBL19557582 0.50 5/20

Clinical trials — most relevant to MAN1B1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients PHASE2ENROLLING_BY_INVITATION
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
Clinical and Basic Investigations Into Congenital Disorders of Glycosylation nanRECRUITING
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
The Natural History of Sialidosis Type I nanRECRUITING
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
Italian Anderson Fabry Disease Cardiovascular Registry nanRECRUITING
Biomarker for Gaucher Disease: BioGaucher (BioGaucher) nanWITHDRAWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11) nanCOMPLETED
Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1) nanCOMPLETED
Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects nanUNKNOWN
Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE) nanRECRUITING
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease nanNO_LONGER_AVAILABLE
Natural History and Genetic Studies of Usher Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAN1B1 binder may also engage these)

ProteinNameSimilarity
B2GUY0 — 0.997 B2GUY0 →
A2AJ15 — 0.989 A2AJ15 →
Q925U4 — 0.988 Q925U4 →
Q92611 — 0.984 Q92611 →
Q6P1J0 — 0.973 Q6P1J0 →
Q6GQB9 — 0.973 Q6GQB9 →
Q9YHB3 — 0.973 Q9YHB3 →
Q93Y37 — 0.971 Q93Y37 →
Q62889 — 0.970 Q62889 →
Q09325 — 0.970 Q09325 →
Q8BYM5 — 0.970 Q8BYM5 →
Q5DTK1 — 0.969 Q5DTK1 →
Q9NZ94 — 0.969 Q9NZ94 →
Q8K1B9 — 0.968 Q8K1B9 →
Q8NHY0 — 0.968 Q8NHY0 →
Q9H2E6 — 0.967 Q9H2E6 →
Q8R4K8 — 0.967 Q8R4K8 →
Q811B1 — 0.967 Q811B1 →
Q8BJT9 — 0.967 Q8BJT9 →
Q9BZQ6 — 0.967 Q9BZQ6 →
Q9NY28 — 0.967 Q9NY28 →
Q9FG93 — 0.967 Q9FG93 →
Q5F2L1 — 0.967 Q5F2L1 →
Q9NR34 — 0.967 Q9NR34 →
Q61139 — 0.966 Q61139 →
Q8NFY4 — 0.966 Q8NFY4 →
Q8JGM4 — 0.966 Q8JGM4 →
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 0.966 landscape →
Q7Z4N8 — 0.966 Q7Z4N8 →
Q80YD1 — 0.966 Q80YD1 →